{"type":"trials","record":{"id":42121,"source_id":"clinicaltrials-gov","external_id":"NCT03525600","title":"Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration","brief_summary":"This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Apellis Pharmaceuticals, Inc.","enrollment":621,"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","France","Germany","Israel","Italy","New Zealand","Poland","Puerto Rico","Spain","United Kingdom"],"start_date":"2018-08-31","completion_date":"2022-06-20","last_update_date":"2023-06-18","source_url":"https://clinicaltrials.gov/study/NCT03525600","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years","comparator":null,"organization":"Apellis Pharmaceuticals, Inc.","interventions":["APL-2","Sham Procedure"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — Baseline (scree…","LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24 — Baseline (screening) and Mo…","Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24 — From Baseline (screening) through Month 24","LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24 — Baseline (screening) and…","LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24 — Baseline (screenin…","LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Geographic Atrophy","APL-2","Sham Procedure"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03525600","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-08-31 to 2022-06-20","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.923Z","intervention":["APL-2","Sham Procedure"],"participants":621,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — Baseline (scree…","LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24 — Baseline (screening) and Mo…","Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24 — From Baseline (screening) through Month 24","LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24 — Baseline (screening) and…","LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24 — Baseline (screenin…","LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42121","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}